Perennial Allergic Rhinitis - Pipeline Review, H2 2012

Global Markets Direct, September 2012, Pages: 48

Perennial Allergic Rhinitis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Perennial Allergic Rhinitis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Perennial Allergic Rhinitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Perennial Allergic Rhinitis. Perennial Allergic Rhinitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Perennial Allergic Rhinitis.
- A review of the Perennial Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Perennial Allergic Rhinitis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Perennial Allergic Rhinitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Perennial Allergic Rhinitis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Perennial Allergic Rhinitis Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Perennial Allergic Rhinitis 7
Perennial Allergic Rhinitis Therapeutics under Development by Companies 9
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Perennial Allergic Rhinitis Therapeutics – Products under Development by Companies 15
Companies Involved in Perennial Allergic Rhinitis Therapeutics Development 16
Shionogi & Co., Ltd. 16
GlaxoSmithKline plc 17
Nycomed International Management GmbH 18
Sun Pharmaceutical Industries Limited 19
GenMont Biotech Inc. 20
VentiRx Pharmaceuticals, Inc. 21
Adamis Pharmaceuticals Corporation 22
Perennial Allergic Rhinitis – Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
ciclesonide - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
VTX-1463 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
S-555739 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
fluticasone furoate - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Modified Allergen Extract - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
GMNL-32 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
SUN-1334 H - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
SUN-1334 H - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
TBS-6 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
APC-3000 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Perennial Allergic Rhinitis Therapeutics – Drug Profile Updates 40
Perennial Allergic Rhinitis Therapeutics - Dormant Products 43
Perennial Allergic Rhinitis – Product Development Milestones 44
Featured News & Press Releases 44
Nov 05, 2011: Sunovion’s Investigational Ciclesonide Nasal Aerosol In HFA Propellant, Demonstrated Positive Results In Patients With Perennial Allergic Rhinitis 44
May 14, 1998: Rhone-Poulenc Rorer submits New Drug Application for once-daily, Non-Sedating Antihistamine 45
Oct 20, 1995: Approval Of Kestine(Ebastine) Received in Denmark; New Antihistamine Now Approved in three European Countries 46
Sep 13, 1994: Rhone-Poulenc Rorer And Fisons Sign Agreements To Market Respiratory Products In Europe 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 48
Disclaimer 48

List of Tables
Number of Products Under Development for Perennial Allergic Rhinitis, H2 2012 7
Products under Development for Perennial Allergic Rhinitis – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Shionogi & Co., Ltd., H2 2012 16
GlaxoSmithKline plc, H2 2012 17
Nycomed International Management GmbH, H2 2012 18
Sun Pharmaceutical Industries Limited, H2 2012 19
GenMont Biotech Inc., H2 2012 20
VentiRx Pharmaceuticals, Inc., H2 2012 21
Adamis Pharmaceuticals Corporation, H2 2012 22
Assessment by Monotherapy Products, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 27
Perennial Allergic Rhinitis Therapeutics – Drug Profile Updates 40
Perennial Allergic Rhinitis Therapeutics – Dormant Products 43

List of Figures
Number of Products under Development for Perennial Allergic Rhinitis, H2 2012 7
Products under Development for Perennial Allergic Rhinitis – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 23
Assessment by Route of Administration, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Molecule Type, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 27

Customers who bought this item also bought

• Allergic Rhinitis - Pipeline Review, H2 2012
• Perennial Allergic Rhinitis - Pipeline Review, H1 2013
• Seasonal Allergic Rhinitis - Pipeline Review, H2 2012
• Allergic Rhinitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
• Allergic Rhinitis Global Clinical Trials Review, H2, 2012
• Allergic Rhinitis - Pipeline Review, H1 2013
• Rhinitis - Pipeline Review, H2 2012
• Allergic Rhinitis - Pipeline Review, H2 2011
• Allergic Asthma - Pipeline Review, H2 2012
• Seasonal Allergic Rhinitis - Pipeline Review, H1 2012